Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Leustat 10mg/10ml solution for infusion vials
0801030C0BBAAAA
|
Leustat | Cladribine | Malignant Disease and Immunosuppression | No data available |
|
Levofolinic acid 200mg/4ml solution for injection vials
0801000Z0AAABAB
|
Levofolinic acid | Levofolinic acid | Malignant Disease and Immunosuppression | No data available |
|
Levofolinic acid 50mg/1ml solution for injection vials
0801000Z0AAAAAA
|
Levofolinic acid | Levofolinic acid | Malignant Disease and Immunosuppression | No data available |
|
Litak 10mg/5ml solution for injection vials
0801030C0BCAAAB
|
Litak | Cladribine | Malignant Disease and Immunosuppression | No data available |
|
Lomustine 100mg capsules
0801010Q0AAADAD
|
Lomustine | Lomustine | Malignant Disease and Immunosuppression | No data available |
|
Lomustine 10mg capsules
0801010Q0AAAAAA
|
Lomustine | Lomustine | Malignant Disease and Immunosuppression | No data available |
|
Lomustine 40mg capsules
0801010Q0AAABAB
|
Lomustine | Lomustine | Malignant Disease and Immunosuppression | No data available |
|
Lonsurf 15mg/6.14mg tablets
0801030AFBBAAAA
|
Lonsurf | Trifluridine/tipiracil | Malignant Disease and Immunosuppression | No data available |
|
Lonsurf 20mg/8.19mg tablets
0801030AFBBABAB
|
Lonsurf | Trifluridine/tipiracil | Malignant Disease and Immunosuppression | No data available |
|
Lutrate 3 month Depot 22.5mg inj vials
0803042N0BCABAE
|
Lutrate | Leuprorelin acetate | Malignant Disease and Immunosuppression | No data available |
|
Lynparza 100mg tablets
0801050BYBBABAB
|
Lynparza | Olaparib | Malignant Disease and Immunosuppression | No data available |
|
Lynparza 150mg tablets
0801050BYBBACAC
|
Lynparza | Olaparib | Malignant Disease and Immunosuppression | No data available |
|
Lynparza 50mg capsules
0801050BYBBAAAA
|
Lynparza | Olaparib | Malignant Disease and Immunosuppression | No data available |
|
Lysodren 500mg tablets
0801050R0BBAAAA
|
Lysodren | Mitotane | Malignant Disease and Immunosuppression | No data available |
|
Lytgobi 4mg tablets
0801050CWBBAAAA
|
Lytgobi | Futibatinib | Malignant Disease and Immunosuppression | No data available |
|
MabCampath 30mg/1ml concentrate for inf vials
0802030E0BBAAAA
|
MabCampath | Alemtuzumab | Malignant Disease and Immunosuppression | No data available |
|
MabThera 100mg/10ml concentrate for inf vials
0802030F0BBABAB
|
MabThera | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
MabThera 1400mg/11.7ml solution for injection vials
0802030F0BBACAC
|
MabThera | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
MabThera 500mg/50ml concentrate for inf vials
0802030F0BBAAAA
|
MabThera | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
Mavenclad 10mg tablets
0802040AYBBAAAA
|
Mavenclad | Cladribine (Immunomodulating) | Malignant Disease and Immunosuppression | No data available |
|
Mayzent 0.25mg tablets
0802040BBBBAAAA
|
Mayzent | Siponimod | Malignant Disease and Immunosuppression | No data available |
|
Mayzent 1mg tablets
0802040BBBBACAC
|
Mayzent | Siponimod | Malignant Disease and Immunosuppression | No data available |
|
Mayzent 2mg tablets
0802040BBBBABAB
|
Mayzent | Siponimod | Malignant Disease and Immunosuppression | No data available |
|
Medroxyprogesterone 100mg/5ml oral liquid
0803020H0AAANAN
|
Medroxyprogest acetate (Cancer) | Medroxyprogesterone acetate | Malignant Disease and Immunosuppression | No data available |
|
Medroxyprogesterone 10mg/5ml oral liquid
0803020H0AAARAR
|
Medroxyprogest acetate (Cancer) | Medroxyprogesterone acetate | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.